Tudor Oprea

Tudor Oprea, M.D., Ph.D.
Professor and Chief, Translational Informatics Division, UNM School
Citation indices All Since 2011
Citations 12837 6393
h-index 58 43
i10-index 141 114
Title1–263 Cited by Year
TIN-X: Target Importance and Novelty Explorer.

DC Cannon, JJ Yang, SL Mathias, O Ursu, S Mani, A Waller, SC Schürer, …
Bioinformatics (Oxford, England)
2017
Protein biomarker druggability profiling

S Mani, D Cannon, R Ohls, T Oprea, S Mathias, K Ballard, O Ursu, …
Journal of Biomedical Informatics 66, 241-247
2017
Drug Target Ontology to Classify and Integrate Drug Discovery Data

Y Lin, S Mehta, HK McGinty, JP Turner, D Vidovic, M Forlin, A Koleti, …
bioRxiv, 117564
2017
A comprehensive Map of molecular drug targets

R Santos, O Ursu, A Gaulton, AP Bento, RS Donadi, CG Bologa, …
Nature Reviews Drug Discovery 16 (1), 19-34
8 2017
Estimation of Maximum Recommended Therapeutic Dose Using Predicted Promiscuity and Potency

T Liu, T Oprea, O Ursu, C Hasselgren, RB Altman
Clinical and Translational Science 9 (6), 311-320
2016
Badapple: promiscuity patterns from noisy evidence

JJ Yang, O Ursu, CA Lipinski, LA Sklar, TI Oprea, CG Bologa
Journal of cheminformatics 8 (1), 1-14
3 2016
Pharos: Collating protein information to shed light on the druggable genome

DT Nguyen, S Mathias, C Bologa, S Brunak, N Fernandez, A Gaulton, …
Nucleic acids research, gkw1072
2 2016
Chronic obstructive pulmonary disease phenotypes using cluster analysis of electronic medical records

R Vazquez Guillamet, O Ursu, G Iwamoto, PL Moseley, T Oprea
Health Informatics Journal, 1460458216675661
2016
DrugCentral: online drug compendium

O Ursu, J Holmes, J Knockel, CG Bologa, JJ Yang, SL Mathias, SJ Nelson, …
Nucleic Acids Research, gkw993
4 2016
A pepducin designed to modulate P2Y 2 R function interacts with FPR2 in human neutrophils and transfers ATP to an NADPH-oxidase-activating ligand through a receptor cross-talk mechanism

M Gabl, A Holdfeldt, M Winther, T Oprea, J Bylund, C Dahlgren, …
Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1863 (6), 1228-1237
5 2016
BDDCS, the rule of 5 and drugability

LZ Benet, CM Hosey, O Ursu, TI Oprea
Advanced drug delivery reviews 101, 89-98
5 2016
Impact of similarity threshold on the topology of molecular similarity networks and clustering outcomes

G Zahoránszky-Kőhalmi, CG Bologa, TI Oprea
Journal of cheminformatics 8 (1), 16
1 2016
Glossary of terms used in computational drug design, part II (IUPAC Recommendations 2015)

YC Martin, R Abagyan, GG Ferenczy, VJ Gillet, TI Oprea, J Ulander, …
Pure and Applied Chemistry 88 (3), 239-264
1 2016
Discovery of a specific inhibitor of human GLUT5 by virtual screening and in vitro transport evaluation

AMG Thompson, O Ursu, P Babkin, CV Iancu, A Whang, TI Oprea, J Choe
Scientific reports 6
4 2016
ChemProt-3.0: a global chemical biology diseases mapping

J Kringelum, SK Kjaerulff, S Brunak, O Lund, TI Oprea, O Taboureau
Database 2016, bav123
3 2016
A novel pharmacologic activity of ketorolac for therapeutic benefit in ovarian cancer patients

Y Guo, SR Kenney, L Cook, SF Adams, T Rutledge, E Romero, TI Oprea, …
Clinical Cancer Research 21 (22), 5064-5072
7 2015
Novel activities of select NSAID R-enantiomers against Rac1 and Cdc42 GTPases

TI Oprea, LA Sklar, JO Agola, Y Guo, M Silberberg, J Roxby, A Vestling, …
PloS one 10 (11), e0142182
4 2015
Modulators of GTPases and their use

AW Ness, L Hudson, L Sklar, Z Surviladze, T Oprea, , T Oprea
US Patent 9,125,899
2015
P2Y 2 receptor signaling in neutrophils is regulated from inside by a novel cytoskeleton-dependent mechanism

M Gabl, M Winther, A Welin, A Karlsson, T Oprea, J Bylund, C Dahlgren, …
Experimental cell research 336 (2), 242-252
4 2015
R-ketorolac targets Cdc42 and Rac1 GTPases and alters ovarian tumor cell behaviors critical for invasion and metastasis

Y Guo, SR Kenney, LA Sklar, T Buranda, TI Oprea, O Ursu, SF Adams, …
Cancer Research 75 (15 Supplement), 4044-4044
1 2015
Modulators of GTPases and Their Use

A Wandinger-Ness, L Hudson, L Sklar, Z Surviladze, T Oprea, , T Oprea
US Patent App. 14/813,874
2015
Advancing biological understanding and therapeutics discovery with small-molecule probes

SL Schreiber, JD Kotz, M Li, J Aubé, CP Austin, JC Reed, H Rosen, …
Cell 161 (6), 1252-1265
34 2015
Clustering Chronic Obstructive Pulmonary Disease Subjects Using Administrative Data

R Vazquez Guillamet, O Ursu, T Oprea, P Moseley, G Iwamoto
B36. COME TOGETHER: COPD PHENOTYPES, A2847-A2847
2015
Ligand‐Directed Profiling of Organelles with Internalizing Phage Libraries

AS Dobroff, R Rangel, L Guzman‐Roja, CC Salmeron, JG Gelovani, …
Current Protocols in Protein Science, 30.4. 1-30.4. 30
2015
Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis

DR Christianson, AS Dobroff, B Proneth, AJ Zurita, A Salameh, …
Proceedings of the National Academy of Sciences 112 (8), 2521-2526
9 2015
CHEMICAL AND BIOLOGICAL DESCRIPTOR INTEGRATION IMPROVES COMPUTATIONAL MODELING OF IN VIVO RAT TOXICITY

CG Bologa, U Oleg, L Halip, R CURPĂN, TI Oprea
Revue roumaine du chimie 60 (2-3), 219
2015
Clustering Chronic Obstructive Pulmonary Disease Subjects Using Administrative Data

RV Guillamet, O Ursu, T Oprea, P Moseley, G Iwamoto
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 191
2015
Computational and Practical Aspects of Drug Repositioning

TI Oprea, JP Overington
Drug Repurposing, Rescue, and Repositioning 1 (1)
7 2015
Defining the microbial effluxome in the content of the host-microbiome interaction

A Ioannidis, M Magana, CG Bologa, TI Oprea, IT Paulsen, GP Tegos
Frontiers in pharmacology 6
2015
FRET detection of lymphocyte function–associated antigen-1 conformational extension

A Chigaev, Y Smagley, MK Haynes, O Ursu, CG Bologa, L Halip, T Oprea, …
Molecular biology of the cell 26 (1), 43-54
2 2015
CFP-10 from Mycobacterium tuberculosis selectively activates human neutrophils through a pertussis toxin-sensitive chemotactic receptor

A Welin, H Björnsdottir, M Winther, K Christenson, T Oprea, A Karlsson, …
Infection and immunity 83 (1), 205-213
8 2015
An automated high-throughput cell-based multiplexed flow cytometry assay to identify novel compounds to target Candida albicans virulence-related proteins

SM Bernardo, CP Allen, A Waller, SM Young, T Oprea, LA Sklar, SA Lee
PloS one 9 (10), e110354
3 2014
Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer

R Hromas, A Leitao, TI Oprea, LA Sklar, EA Williamson, J Wray, W Wang, …
US Patent App. 14/510,476
2014
Methods and related compositions for the treatment of cancer

TA Thompson, D Mackenzie, TI Oprea, LA Sklar, BS Edwards, M Haynes, …
US Patent 8,835,506
2 2014
Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients

AB Jensen, PL Moseley, TI Oprea, SG Ellesøe, R Eriksson, H Schmock, …
Nature communications 5
52 2014
An overview of the challenges in designing, integrating, and delivering BARD: a public chemical-biology resource and query portal for multiple organizations, locations, and disciplines

A De Souza, JA Bittker, DL Lahr, S Brudz, S Chatwin, TI Oprea, A Waller, …
Journal of biomolecular screening 19 (5), 614-627
18 2014
Antibacterial activity of pepducins, allosterical modulators of formyl peptide receptor signaling

M Winther, M Gabl, TI Oprea, B Jönsson, F Boulay, J Bylund, C Dahlgren, …
Antimicrobial agents and chemotherapy 58 (5), 2985-2988
6 2014
A novel receptor cross-talk between the ATP receptor P2Y 2 and formyl peptide receptors reactivates desensitized neutrophils to produce superoxide

K Önnheim, K Christenson, M Gabl, JC Burbiel, CE Müller, TI Oprea, …
Experimental cell research 323 (1), 209-217
13 2014
The University of New Mexico Center for Molecular Discovery

B S Edwards, K Gouveia, T I Oprea, L A Sklar
Combinatorial chemistry & high throughput screening 17 (3), 256-265
3 2014
A systems chemical biology study of malate synthase and isocitrate lyase inhibition in Mycobacterium tuberculosis during active and NRP growth

EE May, A Leitão, A Tropsha, TI Oprea
Computational biology and chemistry 47, 167-180
6 2013
Emerging trends in the discovery of natural product antibacterials

CG Bologa, O Ursu, TI Oprea, CE Melançon, GP Tegos
Current opinion in pharmacology 13 (5), 678-687
25 2013
Abstract B81: Selected NSAIDs target GTPases for ovarian cancer therapy

Y Guo, SR Kenney, E Romero, T Oprea, S Adams, C Muller, L Sklar, …
Clinical Cancer Research 19 (19 Supplement), B81-B81
2 2013
The leukocyte chemotactic receptor FPR2, but not the closely related FPR1, is sensitive to cell-penetrating pepducins with amino acid sequences descending from the third intracellular receptor loop

H Forsman, J Bylund, TI Oprea, A Karlsson, F Boulay, MJ Rabiet, …
Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1833 (8), 1914-1923
23 2013
Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters

JJ Strouse, I Ivnitski-Steele, A Waller, SM Young, D Perez, AM Evangelisti, …
Analytical biochemistry 437 (1), 77-87
19 2013
Modulators of GTPase and Use In Relevant Treatment

A Wandinger-Ness, L Sklar, Z Surviladze, T Oprea, L Hudson, J Aube, …
US Patent App. 13/867,658
1 2013
Characterization of a Cdc42 protein inhibitor and its use as a molecular probe

L Hong, SR Kenney, GK Phillips, D Simpson, CE Schroeder, J Nöth, …
Journal of Biological Chemistry 288 (12), 8531-8543
44 2013
Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in silico/in vitro work flow

I Kouskoumvekaki, RK Petersen, F Fratev, O Taboureau, TE Nielsen, …
Journal of chemical information and modeling 53 (4), 923-937
17 2013
Bradycardic effects mediated by activation of G protein‐coupled estrogen receptor in rat nucleus ambiguus

GC Brailoiu, JB Arterburn, TI Oprea, VC Chitravanshi, E Brailoiu
Experimental physiology 98 (3), 679-691
13 2013
Selective Bcl-2 Inhibitor Probes

J Zou, R Ardecky, AB Pinkerton, E Sergienko, Y Su, D Stonich, RF Curpan, …
National Center for Biotechnology Information (US)
1 2013
Profiling a Selective Probe for RTG Branch of Yeast TORC1 Signaling Pathway

J Chen, SM Young, C Allen, A Waller, O Ursu, JJ Strouse, T Yao, …
National Center for Biotechnology Information (US)
2 2013
Selective efflux inhibition of ATP-binding cassette sub-family G member 2

JJ Strouse, I Ivnitski-Steele, HM Njus, TD Foutz, T Yao, WS Weiner, …
National Center for Biotechnology Information (US)
4 2013
A chemogenomic analysis of ionization constants—implications for drug discovery

DT Manallack, RJ Prankerd, GC Nassta, O Ursu, TI Oprea, DK Chalmers
ChemMedChem 8 (2), 242-255
9 2013
A selective ATP-binding cassette subfamily G member 2 efflux inhibitor revealed via high-throughput flow cytometry

JJ Strouse, I Ivnitski-Steele, HM Khawaja, D Perez, J Ricci, T Yao, …
Journal of biomolecular screening 18 (1), 26-38
10 2013
UNM Division of Biocomputing public web applications: Computational tools for cheminformatics and molecular discovery

TI Oprea, C Bologa, S Mathias, J Abear, O Ursu, G Zahoransky-Kohalmi, …
2013
The CARLSBAD database: a confederated database of chemical bioactivities

SL Mathias, J Hines-Kay, JJ Yang, G Zahoransky-Kohalmi, CG Bologa, …
Database 2013, bat044
9 2013
The significance of acid/base properties in drug discovery

DT Manallack, RJ Prankerd, E Yuriev, TI Oprea, DK Chalmers
Chemical Society Reviews 42 (2), 485-496
37 2013
ChemProt-2.0: visual navigation in a disease chemical biology database

SK Kjærulff, L Wich, J Kringelum, UP Jacobsen, I Kouskoumvekaki, …
Nucleic acids research 41 (D1), D464-D469
43 2013
Targeting the transposase domain of the DNA repair component Metnase to enhance chemotherapy

EA Williamson, L Damiani, A Leitao, C Hu, H Hathaway, T Oprea, L Sklar, …
Cancer research 72 (23), 6200-6208
23 2012
Drug repurposing: far beyond new targets for old drugs

TI Oprea, J Mestres
The AAPS journal 14 (4), 759-763
58 2012
Fitting the complexity of GPCRs modulation into simple hypotheses of ligand design

C Custodi, R Nuti, TI Oprea, A Macchiarulo
Journal of Molecular Graphics and Modelling 38, 70-81
5 2012
Mechanisms of G protein-coupled estrogen receptor-mediated spinal nociception

E Deliu, GC Brailoiu, JB Arterburn, TI Oprea, K Benamar, NJ Dun, …
The Journal of Pain 13 (8), 742-754
18 2012
A novel flow cytometric HTS assay reveals functional modulators of ATP binding cassette transporter ABCB6

K Polireddy, MMT Khan, H Chavan, S Young, X Ma, A Waller, M Garcia, …
PloS one 7 (7), e40005
10 2012
A non-peptide receptor inhibitor with selectivity for one of the neutrophil formyl peptide receptors, FPR 1

H Çevik-Aras, C Kalderén, AJ Jensen, T Oprea, C Dahlgren, H Forsman
Biochemical pharmacology 83 (12), 1655-1662
16 2012
A competitive nucleotide binding inhibitor: in vitro characterization of Rab7 GTPase inhibition

JO Agola, L Hong, Z Surviladze, O Ursu, A Waller, JJ Strouse, …
ACS chemical biology 7 (6), 1095
38 2012
A pilot study of raltegravir and cisplatin in head and neck squamous cell carcinoma (HNSCC).

JE Bauman, GT Olson, M Spafford, M Nuara, S Sampath, SJ Lee, …
Journal of Clinical Oncology 30 (15_suppl), TPS5602-TPS5602
2012
Selective inhibition of Rac1 and Cdc42 in ovarian cancer using the R-enantiomer of ketorolac

SR Kenney, T Oprea, O Ursu, L Sklar, L Lomo, C Muller, Y Gao, …
Cancer Research 72 (8 Supplement), 910-910
1 2012
BDDCS class prediction for new molecular entities

F Broccatelli, G Cruciani, LZ Benet, TI Oprea
Molecular pharmaceutics 9 (3), 570
53 2012
System chemical biology studies of endocrine disruptors

O Taboureau, TI Oprea
2012
Specific Cell-Permeant Cdc42 Inhibitor Prevents GTPase Activation and Cellular Functions

A Wandinger-Ness, L Hong, SR Kenney, GK Phillips, D Simpson, …
MOLECULAR BIOLOGY OF THE CELL 23
2012
Compound collection preparation for virtual screening

CG Bologa, TI Oprea
Bioinformatics and Drug Discovery, 125-143
4 2012
Of possible cheminformatics futures

TI Oprea, O Taboureau, CG Bologa
Journal of computer-aided molecular design 26 (1), 107-112
8 2012
Improving the prediction of the brain disposition for orally administered drugs using BDDCS

F Broccatelli, CA Larregieu, G Cruciani, TI Oprea, LZ Benet
Advanced Drug Delivery Reviews 64 (1), 95–109
41 2011
BDDCS applied to over 900 drugs

LZ Benet, F Broccatelli, TI Oprea
The AAPS journal 13 (4), 519-547
255 2011
Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity

MK Dennis, AS Field, R Burai, C Ramesh, WK Petrie, CG Bologa, …
The Journal of steroid biochemistry and molecular biology 127 (3), 358-366
129 2011
Drug repurposing from an academic perspective

TI Oprea, JE Bauman, CG Bologa, T Buranda, A Chigaev, BS Edwards, …
Drug Discovery Today: Therapeutic Strategies 8 (3-4), 61-69
83 2011
Drug-like physicochemical properties

PD Leeson, TI Oprea
Drug Design Strategies, 35-59
8 2011
G protein-coupled estrogen receptor 1-mediated effects in the rat myometrium

AA Tica, EC Dun, OS Tica, X Gao, JB Arterburn, GC Brailoiu, TI Oprea, …
American Journal of Physiology-Cell Physiology 301 (5), C1262-C1269
27 2011
Linking Pharmacology to Clinical Reports: Cyclobenzaprine and Its Possible Association With Serotonin Syndrome

J Mestres, SA Seifert, TI Oprea
Clinical Pharmacology & Therapeutics 90, 662-665
33 2011
High-throughput screen for the chemical inhibitors of antiapoptotic bcl-2 family proteins by multiplex flow cytometry

RF Curpan, PC Simons, D Zhai, SM Young, MB Carter, CG Bologa, …
Assay and drug development technologies 9 (5), 465-474
15 2011
Understanding drug‐likeness

O Ursu, A Rayan, A Goldblum, TI Oprea
Wiley Interdisciplinary Reviews: Computational Molecular Science 1 (5), 760-781
62 2011
Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide

GC Brailoiu, TI Oprea, P Zhao, ME Abood, E Brailoiu
Journal of Biological Chemistry 286 (33), 29166-29174
52 2011
Cross-pharmacology analysis of G protein-coupled receptors

F Briansó, M C Carrascosa, T I Oprea, J Mestres
Current topics in medicinal chemistry 11 (15), 1956-1963
26 2011
Microbial efflux pump inhibition: tactics and strategies

G P Tegos, M Haynes, J Jacob Strouse, M Md T Khan, C G Bologa, …
Current pharmaceutical design 17 (13), 1291-1302
50 2011
Abstract LB-214: Rac1 and Cdc42 GTPases as novel targets in ovarian cancer

A Wandinger-Ness, SR Kenney, J Agola, J Roxby, Z Surviladze, …
Cancer Research 71 (8 Supplement), LB-214-LB-214
2011
Models of the algistatic activity of 5-amino-1-aryl-1H-tetrazoles

M Mracec, TI Oprea, M Mracec
Rev Roum Chim 56 (4), 373-379
2 2011
A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields

F Broccatelli, E Carosati, A Neri, M Frosini, L Goracci, TI Oprea, …
Journal of medicinal chemistry 54 (6), 1740
78 2011
Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New Platform for Computer‐Aided Drug Repurposing

TI Oprea, SK Nielsen, O Ursu, JJ Yang, O Taboureau, SL Mathias, …
Molecular informatics 30 (2‐3), 100-111
67 2011
Next‐generation QSAR

TI Oprea
Molecular Informatics 30 (2‐3), 89-89
1 2011
Compounds for binding to ERα/β and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof

ER Prossnitz, SE Tkatchenko, CM Revankar, LA Sklar, JB Arterburn, …
US Patent 7,875,721
1 2011
Enantiomer specific inhibition of Rac1 and Cdc42 in ovarian cancer

SR Kenney, J Roxby, E Romero, O Ursu, T Oprea, L Sklar, …
MOLECULAR BIOLOGY OF THE CELL 22
1 2011
Cheminformatics-Basics: Molecular Descriptors and Fingerprints

DC Fara, TI Oprea
1 2011
Computational systems chemical biology

TI Oprea, EE May, A Leitão, A Tropsha
Chemoinformatics and Computational Chemical Biology, 459-488
18 2011
ChemProt: a disease chemical biology database

O Taboureau, SK Nielsen, K Audouze, N Weinhold, D Edsgärd, FS Roque, …
Nucleic acids research 39 (suppl 1), D367-D372
54 2011
Small molecule inhibitors of hantavirus infection

PR Hall, A Leitão, C Ye, K Kilpatrick, B Hjelle, TI Oprea, RS Larson
Bioorganic & medicinal chemistry letters 20 (23), 7085-7091
12 2010
Three small molecule pan activator families of Ras-related GTPases

Z Surviladze, O Ursu, F Miscioscia, R Curpan, L Halip, C Bologa, T Oprea, …
National Center for Biotechnology Information (US)
7 2010
Model-free drug-likeness from fragments

O Ursu, TI Oprea
Journal of chemical information and modeling 50 (8), 1387-1394
15 2010
Modulation of bitter taste perception by a small molecule hTAS2R antagonist

JP Slack, A Brockhoff, C Batram, S Menzel, C Sonnabend, S Born, …
Current Biology 20 (12), 1104-1109
90 2010
Novel derivatives of 1, 3, 4-oxadiazoles are potent mitostatic agents featuring strong microtubule depolymerizing activity in the sea urchin embryo and cell culture assays

AS Kiselyov, MN Semenova, NB Chernyshova, A Leitao, AV Samet, …
European journal of medicinal chemistry 45 (5), 1683-1697
62 2010
A Scaffold‐Tree‐Merging Strategy for Prospective Bioactivity Annotation of γ‐Pyrones

S Wetzel, W Wilk, S Chammaa, B Sperl, AG Roth, A Yektaoglu, S Renner, …
Angewandte Chemie International Edition 49 (21), 3666-3670
31 2010
iPHACE: integrative navigation in pharmacological space

R Garcia-Serna, O Ursu, TI Oprea, J Mestres
Bioinformatics 26 (7), 985-986
22 2010
Metnase and intnase inhibitors and their use in treating cancer

R Hromas, A Leitao, TI Oprea, LA Sklar, EA Williamson, J Wray, , J Wray, …
US Patent App. 13/255,708
2010
Highly Efficient Synthesis and Characterization of the GPR30‐Selective Agonist G‐1 and Related Tetrahydroquinoline Analogues.

R Burai, C Ramesh, M Shorty, R Curpan, C Bologa, LA Sklar, T Oprea, …
Organic & biomolecular chemistry 8 (9), 2252-2259
27 2010
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors

MJ Saunders, SW Graves, LA Sklar, TI Oprea, BS Edwards
Assay and drug development technologies 8 (1), 37-46
21 2010
The G protein–coupled receptor GPR30 inhibits proliferation of estrogen receptor–positive breast cancer cells

EA Ariazi, E Brailoiu, S Yerrum, HA Shupp, MJ Slifker, HE Cunliffe, …
Cancer research 70 (3), 1184-1194
161 2010
Transporter‐Mediated Efflux Influences CNS Side Effects: ABCB1, from Antitarget to Target

F Broccatelli, E Carosati, G Cruciani, TI Oprea
Molecular informatics 29 (1‐2), 16-26
26 2010
Highly efficient synthesis and characterization of the GPR30-selective agonist G-1 and related tetrahydroquinoline analogs

M Shorty, C Bologa, J B Arterburn, C Ramesh, L A Sklar, E R Prossnitz, …
The Royal Society of Chemistry
2010
Databases for chemical and biological information

TI Oprea, L Ostopovici‐Halip, R Rad‐curpan
Pharmaceutical Data Mining: Approaches and Applications for Drug Discovery …
2 2010
High‐Throughput Flow Cytometry

LA Sklar, PC Simons, A Waller, SM Biggs, SM Young, M Olah, C Bologa, …
Pharmaceutical Sciences Encyclopedia
1 2010
Conformational mAb as a tool for integrin ligand discovery

BH Njus, A Chigaev, A Waller, D Wlodek, L Ostopovici-Halip, O Ursu, …
Assay and drug development technologies 7 (5), 507-515
16 2009
Estrogen rapidly modulates 5-hydroxytrytophan-induced visceral hypersensitivity via GPR30 in rats

CL Lu, JC Hsieh, NJ Dun, TI Oprea, PS Wang, JC Luo, HC Lin, FY Chang, …
Gastroenterology 137 (3), 1040-1050
37 2009
Corrigendum: Chromatin-level regulation of biosynthetic gene clusters

JW Bok, YM Chiang, E Szewczyk, Y Reyes-Dominguez, AD Davidson, …
Nature Chemical Biology 5 (9), 696
2009
Corrigendum: Interactive exploration of chemical space with Scaffold Hunter

S Wetzel, K Klein, S Renner, D Rauh, TI Oprea, P Mutzel, H Waldmann
Nature Chemical Biology 5 (9), 696
5 2009
A crowdsourcing evaluation of the NIH chemical probes (vol 5, pg 441, 2009)

TI Oprea, CG Bologa, S Boyer, RF Curpan, RC Glen, AL Hopkins, …
NATURE CHEMICAL BIOLOGY 5 (8), 600-600
2009
Erratum: A crowdsourcing evaluation of the NIH chemical probes

TI Oprea, CG Bologa, S Boyer, RF Curpan, RC Glen, AL Hopkins, …
Nature Chemical Biology 5 (8), 600
2009
Bioactivity-guided mapping and navigation of chemical space

S Renner, WAL Van Otterlo, MD Seoane, S Möcklinghoff, B Hofmann, …
Nature chemical biology 5 (8), 585-592
94 2009
Interactive exploration of chemical space with Scaffold Hunter

S Wetzel, K Klein, S Renner, D Rauh, TI Oprea, P Mutzel, H Waldmann
Nature chemical biology 5 (8), 581-583
150 2009
A crowdsourcing evaluation of the NIH chemical probes

TI Oprea, CG Bologa, S Boyer, RF Curpan, RC Glen, AL Hopkins, …
Nature chemical biology 5 (7), 441-447
89 2009
Detection of intracellular granularity induction in prostate cancer cell lines by small molecules using the HyperCyt® high-throughput flow cytometry system

MK Haynes, JJ Strouse, A Waller, A Leitao, RF Curpan, C Bologa, …
Journal of biomolecular screening 14 (6), 596-609
17 2009
In vivo effects of a GPR30 antagonist

MK Dennis, R Burai, C Ramesh, WK Petrie, SN Alcon, TK Nayak, …
Nature chemical biology 5 (6), 421-427
321 2009
Expression of estrogen receptor GPR30 in the rat spinal cord and in autonomic and sensory ganglia

SL Dun, GC Brailoiu, X Gao, E Brailoiu, JB Arterburn, ER Prossnitz, …
Journal of neuroscience research 87 (7), 1610-1619
62 2009
High-throughput screening of small molecule inducers of autophagy as potential therapies for prostate cancer

D MacKenzie, M Haynes, CA Hu, L Skalr, T Oprea, C Bologa, …
CANCER RESEARCH 69
2 2009
Abstract# 5505: High-throughput screening of small molecule inducers of autophagy as potential therapies for prostate cancer

D MacKenzie, M Haynes, CA Hu, L Sklar, T Oprea, C Bologa, …
Cancer Research 69 (9 Supplement), 5505-5505
2009
Novel chemical space exploration via natural products

J Rosén, J Gottfries, S Muresan, A Backlund, TI Oprea
Journal of medicinal chemistry 52 (7), 1953
158 2009
Cytochrome P450s in DrugMetabolism and Disease

TI Oprea
2009
Duplex high‐throughput flow cytometry screen identifies two novel formylpeptide receptor family probes

SM Young, CM Bologa, D Fara, BK Bryant, JJ Strouse, JB Arterburn, …
Cytometry Part A 75 (3), 253-263
30 2009
Vascular responses mediated by GPR30/GPER

E Brailoiu, AA Tica, CG Brailoiu, JB Arterburn, M Barton, ER Prossnitz, …
Proceedings of The Physiological Society
2009
Discovery of Selective Probes and Antagonists for G Protein-Coupled Receptors FPR/FPRL1 and GPR30

JB Arterburn, TI Oprea, ER Prossnitz, BS Edwards, LA Sklar
Current topics in medicinal chemistry 9 (13), 1227–1236
21 2009
Compounds and methods for the selective inhibition of ABCB1, ABCC1 and ABCG2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors

RS Larson, LA Sklar, BS Edwards, ID Ivnitski-Steele, TI Oprea, DM Lovato, …
US Patent App. 12/315,132
1 2008
Systems chemical biology studies of enzymatic metabolic networks and inhibitors.

E May, M Misra, JL Faulon, A Leitao, TI Oprea
Sandia National Laboratories (SNL-NM), Albuquerque, NM (United States)
2008
Molecular similarity analysis in virtual screening

L Peltason, J Bajorath
Chemoinformatics Approaches to Virtual Screening, 120-149
10* 2008
Understanding virulence mechanisms in M. tuberculosis infection via a circuit-based simulation framework

E May, A Leitao, JL Faulon, J Joo, M Misra, TI Oprea
Engineering in Medicine and Biology Society, 2008. EMBS 2008. 30th Annual …
5 2008
Efficient calculation of molecular properties from simulation using kernel molecular dynamics

WM Brown, A Sasson, DR Bellew, LA Hunsaker, S Martin, A Leitao, …
Journal of chemical information and modeling 48 (8), 1626-1637
5 2008
Is there a general model for bioactivity? An overview of the MLSMR-MLSCN bioassays

TI Oprea
JOURNAL OF BIOMOLECULAR SCREENING 13 (7), 713-714
2008
QSAR modeling of the blood–brain barrier permeability for diverse organic compounds

L Zhang, H Zhu, TI Oprea, A Golbraikh, A Tropsha
Pharmaceutical research 25 (8), 1902
115 2008
Quantifying the Relationships among Drug Classes.

J Hert, MJ Keiser, JJ Irwin, TI Oprea, BK Shoichet
Journal of chemical information and modeling 48 (4), 755–765
135 2008
Scaffold topologies I: exhaustive enumeration up to 8 rings

SN Pollock, EA Coutsias, MJ Wester, TI Oprea
Journal of chemical information and modeling 48 (7), 1304
26 2008
Scaffold Topologies II: Analysis of Chemical Databases

MJ Wester, S Pollock, EA Coutsias, TK Allu, S Muresan, TI Oprea
Journal of chemical information and modeling 48 (7), 1311
36 2008
The ins and outs of GPR30: a transmembrane estrogen receptor

ER Prossnitz, TI Oprea, LA Sklar, JB Arterburn
The Journal of steroid biochemistry and molecular biology 109 (3), 350-353
148 2008
High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters

I Ivnitski-Steele, RS Larson, DM Lovato, HM Khawaja, SS Winter, TI Oprea, …
Assay and drug development technologies 6 (2), 263-276
43 2008
GPR30: a novel therapeutic target in estrogen-related disease

ER Prossnitz, LA Sklar, TI Oprea, JB Arterburn
Trends in pharmacological sciences 29 (3), 116-123
111 2008
Estrogen signaling through the transmembrane G protein–coupled receptor GPR30

ER Prossnitz, JB Arterburn, HO Smith, TI Oprea, LA Sklar, HJ Hathaway
Annu. Rev. Physiol. 70, 165-190
468 2008
High-throughput screening for daunorubicin-mediated drug resistance identifies mometasone furoate as a novel ABCB1-reversal agent

SS Winter, DM Lovato, HM Khawaja, BS Edwards, ID Steele, SM Young, …
Journal of biomolecular screening 13 (3), 185-193
30 2008
Optimization of CAMD techniques 3. Virtual screening enrichment studies: a help or hindrance in tool selection?

AC Good, TI Oprea
Journal of computer-aided molecular design 22 (3-4), 169-178
142 2008
hERG classification model based on a combination of support vector machine method and GRIND descriptors

Q Li, FS Jørgensen, T Oprea, S Brunak, O Taboureau
Molecular pharmaceutics 5 (1), 117-127
78 2008
2D QSAR and similarity studies on cruzain inhibitors aimed at improving selectivity over cathepsin L

RF Freitas, TI Oprea, CA Montanari
Bioorganic & medicinal chemistry 16 (2), 838-853
28 2008
WOMBAT and WOMBAT‐PK: bioactivity databases for lead and drug discovery

M Olah, R Rad, L Ostopovici, A Bora, N Hadaruga, D Hadaruga, …
Chemical Biology: From Small Molecules to Systems Biology and Drug Design …
78 2008
Sense and nonsense in drug discovery: a chemical perspective

TI Oprea
Towards Drugs of the Future: Key Issues in Lead Finding and Lead …
2* 2008
Exemestane’s 17-hydroxylated metabolite exerts biological effects as an androgen

EA Ariazi, A Leitao, TI Oprea, B Chen, T Louis, AM Bertucci, CGN Sharma, …
Molecular cancer therapeutics 6 (11), 2817-2827
44 2007
Virtual screening applications: a study of ligand-based methods and different structure representations in four different scenarios

DP Hristozov, TI Oprea, J Gasteiger
Journal of computer-aided molecular design 21 (10-11), 617-640
40 2007
Ligand‐Based Virtual Screening by Novelty Detection with Self‐Organizing Maps.

D Hristozov, TI Oprea, J Gasteiger
Journal of chemical information and modeling 47 (6), 2044–2062
22 2007
The privileged structures hypothesis for G protein-coupled receptors-some preliminary results

R RAD, M Mracec, M Mraceca, T Oprea
REVUE ROUMAINE DE CHIMIE 52 (8-9), 853-+
3 2007
Systems chemical biology

TI Oprea, A Tropsha, JL Faulon, MD Rintoul
Nature chemical biology 3 (8), 447-450
129 2007
Activation of dioxin response element (DRE)-associated genes by benzo (a) pyrene 3, 6-quinone and benzo (a) pyrene 1, 6-quinone in MCF-10A human mammary epithelial cells

SW Burchiel, TA Thompson, FT Lauer, TI Oprea
Toxicology and applied pharmacology 221 (2), 203-214
46 2007
High-throughput flow cytometry for drug discovery

BS Edwards, SM Young, MJ Saunders, C Bologa, TI Oprea, RD Ye, …
Expert opinion on drug discovery 2 (5), 685-696
26 2007
In vitro differentiation of human mesenchymal stem cells to epithelial lineage

V Păunescu, E Deak, D Herman, IR Siska, C Bunu, S Anghel, CA Tatu, …
Journal of cellular and molecular medicine 11 (3), 502-508
127 2007
Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system

E Brailoiu, SL Dun, GC Brailoiu, K Mizuo, LA Sklar, TI Oprea, ER Prossnitz, …
Journal of Endocrinology 193 (2), 311-321
329 2007
Integration of virtual and physical screening

DC Fara, TI Oprea, ER Prossnitz, CG Bologa, BS Edwards, LA Sklar
Drug Discovery Today: Technologies 3 (4), 377-385
24 2007
Target, chemical and bioactivity databases–integration is key

TI Oprea, A Tropsha
Drug Discovery Today: Technologies 3 (4), 357-365
55 2007
G protein–coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17β-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells

L Albanito, A Madeo, R Lappano, A Vivacqua, V Rago, A Carpino, …
Cancer research 67 (4), 1859-1866
341 2007
Rü ster, B., Bistrian, R., and Seifried, E

V Paunescu, E Deak, D Herman, IR Siska, G Tanasie, C Bunu, S Anghel, …
vitro differentiation of human mesenchymal stem cells to epithelial lineage …
2 2007
Theoretical and Practical Aspects of Three‐Dimensional Quantitative Structure‐Activity Relationships

TI Oprea, CL Waller
Reviews in Computational Chemistry, Volume 11, 127-182
66 2007
Lead-like, drug-like or “Pub-like”: how different are they?

TI Oprea, TK Allu, DC Fara, RF Rad, L Ostopovici, CG Bologa
Journal of computer-aided molecular design 21 (1-3), 113-119
99 2007
Novel targets for the NIH Roadman Molecular Libraries Initiative

LA Sklar, J Arterburn, B Edwards, A Kiselyov, T Oprea, E Prossnitz
NEUROPSYCHOPHARMACOLOGY 31, S65-S66
2006
Identification of Off-Patent Drugs That Reverse Daunorubicin Efflux Mediated by ABCB1 in T-ALL Cells.

SS Winter, DM Lovato, HM Khawaja, BS Edwards, ID Steele, SM Young, …
Blood 108 (11), 2603-2603
2006
Steroid-binding G-protein-coupled receptors: new drug discovery targets for old ligands

ER Prossnitz, JB Arterburn, BS Edwards, LA Sklar, TI Oprea
Expert opinion on drug discovery 1 (2), 137-150
7 2006
Biomolecular screening of formylpeptide receptor ligands with a sensitive, quantitative, high-throughput flow cytometry platform

BS Edwards, SM Young, TI Oprea, CG Bologa, ER Prossnitz, LA Sklar
NATURE PROTOCOLS-ELECTRONIC EDITION- 1 (1), 59
29 2006
Flow cytometry and the NIH Roadmap Molecular Libraries Screening Initiative

BS Edwards, J Arterburn, S Biggs, C Bologa, T Buranda, D Cimino, …
CYTOMETRY PART A 69 (5), 409-409
2006
Virtual and biomolecular screening converge on a selective agonist for GPR30

CG Bologa, CM Revankar, SM Young, BS Edwards, JB Arterburn, …
Nature chemical biology 2 (4), 207-212
566 2006
Oncology exploration: charting cancer medicinal chemistry space

DG Lloyd, G Golfis, AJS Knox, D Fayne, MJ Meegan, TI Oprea
Drug discovery today 11 (3), 149-159
45 2006
QSAR and Molecular Modelling in Rational Design of Bioactive Molecules

TI Oprea, MA Kappler, TK Allu, M Mracec, MM Olah, R Rad, L Ostopovici, …
Computer Aided Drug Design & Development Society in Turkey
4 2006
Bioactivity databases

M Olah, TI Oprea
Comprehensive Medicinal Chemistry II 3, 293-313
6 2006
Cheminformatics Approaches to Fragment‐based Lead Discovery

TI Oprea, JM Blaney
Fragment-based approaches in drug discovery, 89-111
10 2006
Chemical database preparation for compound acquisition or virtual screening

CG Bologa, MM Olah, TI Oprea
Bioinformatics and Drug Discovery, 375-388
21 2006
Cheminformatics and drug discovery

TI Oprea, A Tropsha
Drug Discovery Today: Technologies 3 (4), 355-356
1 2006
Rapid ADME filters for lead discovery

TI Oprea, P Benedetti, G Berellini, M Olah, K Fejgin, S Boyer
Molecular Interaction Fields: Applications in Drug Discovery and ADME …
2 2006
Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists

BS Edwards, C Bologa, SM Young, KV Balakin, ER Prossnitz, …
Molecular pharmacology 68 (5), 1301-1310
101 2005
Rapid evaluation of synthetic and molecular complexity for in silico chemistry

TK Allu, TI Oprea
Journal of chemical information and modeling 45 (5), 1237-1243
43 2005
Surrogate data–a secure way to share corporate data

IV Tetko, R Abagyan, TI Oprea
Journal of computer-aided molecular design 19 (9), 749-764
11 2005
Descriptor collision and confusion: Toward the design of descriptors to mask chemical structures

C Bologa, TK Allu, M Olah, MA Kappler, TI Oprea
Journal of computer-aided molecular design 19 (9), 625-635
14 2005
MTD-PLS: A PLS variant of the minimal topologic difference method. III. Mapping interactions between estradiol derivatives and the alpha estrogenic receptor

L Kurunczi, E Seclaman, TI Oprea, L Crisan, Z Simon
Journal of chemical information and modeling 45 (5), 1275-1281
24 2005
Post-high-throughput screening analysis: an empirical compound prioritization scheme

TI Oprea, CG Bologa, BS Edwards, ER Prossnitz, LA Sklar
Journal of biomolecular screening 10 (5), 419-426
19 2005
High-throughput screening with HyperCyt® flow cytometry to detect small molecule formylpeptide receptor ligands

SM Young, C Bologa, ER Prossnitz, TI Oprea, LA Sklar, BS Edwards
Journal of biomolecular screening 10 (4), 374-382
59 2005
Compound selection for virtual screening

TI Oprea, C Bologa, M Olah
Virtual Screening in Drug Discovery, 89-106
12* 2005
Dissociation of I Domain and Global Conformational Changes in LFA-1: Refinement of Small Molecule-I Domain Structure− Activity Relationships

RS Larson, T Davis, C Bologa, G Semenuk, S Vijayan, Y Li, T Oprea, …
Biochemistry 44 (11), 4322-4331
41 2005
Cheminformatics in drug discovery (Methods and Principles in Medicinal Chemistry vol. 23)

TI OPREA
Wiley-VCH 1, 493
86* 2005
Isolation and purification of human insulin producing cells for the treatment of insulin dependent diabetes

V Paunescu, E Suciu, C Tatu, T Oprea, , T Oprea, , , T Oprea, , , , T Oprea
US Patent App. 11/029,541
2005
WOMBAT: world of molecular bioactivity

M Olah, M Mracec, L Ostopovici, R Rad, A Bora, N Hadaruga, I Olah, …
Chemoinformatics in drug discovery 1, 223-239
130 2005
Strategies for compound selection

MM Olah, CG Bologa, TI Oprea
Current drug discovery technologies 1 (3), 211-220
76 2004
Flow cytometry for high-throughput, high-content screening

BS Edwards, T Oprea, ER Prossnitz, LA Sklar
Current opinion in chemical biology 8 (4), 392-398
197 2004
Integrating virtual screening in lead discovery

TI Oprea, H Matter
Current opinion in chemical biology 8 (4), 349-358
258 2004
Next-generation therapeutics

T Oprea
Current opinion in Chemical biology 8 (4), 347-348
1 2004
An automated PLS search for biologically relevant QSAR descriptors

M Olah, C Bologa, TI Oprea
Journal of computer-aided molecular design 18 (7-9), 437-449
77 2004
Pursuing the leadlikeness concept in pharmaceutical research

MM Hann, TI Oprea
Current opinion in chemical biology 8 (3), 255-263
428 2004
Screening with HyperCyt (R) high-throughput flow cytometry to detect small-molecule formyl-peptide receptor ligands

BS Edwards, SM Young, A Waller, C Bologa, T Oprea, ER Prossnitz, …
CYTOMETRY PART A 59 (1), 31-32
2004
Global method for mapping property spaces

J Gottfries, T Oprea
US Patent 6,675,136
8* 2004
In silico lead optimization

CMW Ho
Chemoinformatics in drug discovery, 199-219
3 2004
Enhancing hit quality and diversity within assay throughput constraints

I McFadyen, G Walker, J Alvarez
Chemoinformatics in Drug Discovery, 141-173
8 2004
Chemoinformatics in lead discovery

TI Oprea
Chemoinformatics in Drug Discovery, 23-41
7 2004
3D QSAR modeling in drug design

TI Oprea
Computational Medicinal Chemistry for drug discovery, 571-616
86* 2004
Surface descriptors for protein-ligand affinity prediction

I Zamora, T Oprea, G Cruciani, M Pastor, AL Ungell
Journal of medicinal chemistry 46 (1), 25-33
66 2003
Chemoinformatics and the quest for leads in drug discovery

TI Oprea
Handbook of Chemoinformatics: From Data to Knowledge in 4 Volumes, 1508-1531
11 2003
On the information content of 2D and 3D descriptors for QSAR

TI Oprea
Journal of the Brazilian Chemical Society 13 (6), 811-815
25 2002
Distant collaboration in drug discovery: The LINK3D project

M Pastor, P Benedetti, A Carotti, A Carrieri, C Diaz, C Herraiz, HD Höltje, …
Journal of computer-aided molecular design 16 (11), 809-818
6 2002
MTD-PLS: A PLS-based variant of the MTD method. 2. Mapping ligand-receptor interactions. Enzymatic acetic acid esters hydrolysis

L Kurunczi, M Olah, TI Oprea, C Bologa, Z Simon
Journal of chemical information and computer sciences 42 (4), 841-846
15 2002
Pharmacokinetically based mapping device for chemical space navigation

TI Oprea, I Zamora, AL Ungell
Journal of combinatorial chemistry 4 (4), 258-266
79 2002
Chemical space navigation in lead discovery

TI Oprea
Current opinion in chemical biology 6 (3), 384-389
84 2002
Current trends in lead discovery: Are we looking at the appropriate property

TI Oprea
Journal of computer-aided molecular design 16 (5-6), 325-334
246 2002
Current trends in lead discovery: Are we looking for the appropriate properties?

TI Oprea
Journal of computer-aided molecular design 16 (5-6), 325-334
234 2002
Virtual screening in lead discovery: a viewpoint

TI Oprea
Molecules 7 (1), 51-62
107 2002
Quantum Biochemistry and Specific Interactions: The QSAR and Quantum Chemistry Group of Timisoara

A Chiriac
Mirton
3 2002
Science in post-communist Romania

L Giosan, T Oprea
Ad Astra 1 (2)
6* 2002
High throughput and virtual screening: choosing the appropriate leads

TI Oprea, J Li, S Muresan, KC Mattes
EuroQSAR, 40-47
5 2002
On the propagation of errors in the QSAR literature

TI Oprea, M Olah, L Ostopovici, R Rad, M Mracec
EuroQSAR 2002 – Designing Drugs and crop protectants: processes, problems …
9 2002
Is There a Difference Between Leads and Drugs? A Historical Perspective.

TI Oprea, AM Davis, SJ Teague, PD Leeson
Journal of chemical information and computer sciences 41 (5), 1308-1315
712 2001
Solid-phase synthesis of libraries generated from a 4-phenyl-2-carboxy-piperazine scaffold

JW Nilsson, F Thorstensson, I Kvarnström, T Oprea, B Samuelsson, …
Journal of combinatorial chemistry 3 (6), 546-553
34 2001
Cheminformatics: a tool for decision-makers in drug discovery.

T Olsson, TI Oprea
Current opinion in drug discovery & development 4 (3), 308-313
48 2001
Rapid estimation of hydrophobicity for virtual combinatorial library analysis

TI Oprea
SAR and QSAR in Environmental Research 12 (1-2), 129-141
15 2001
MTD-PLS: A PLS-based variant of the MTD method. A 3D-QSAR analysis of receptor affinities for a series of halogenated dibenzoxin and biphenyl derivatives

TI Oprea, L Kurunczi, M Olah, Z Simon
SAR and QSAR in Environmental Research 12 (1-2), 75-92
19 2001
Chemography: the art of navigating in chemical space

TI Oprea, J Gottfries
Journal of combinatorial chemistry 3 (2), 157-166
264 2001
De veghe în cercetarea românească

TI Oprea, AT Balaban
Mirton
5 2001
Qvo vadis, scoring functions? Toward an integrated pharmacokinetic and binding Affinity Prediction Framework

TI Oprea, I Zamora, P Svensson
Combinatorial library design and eValuation for drug design, 233-266
11 2001
Prediction of oral drug permeability

I Zamora, TI Oprea, AL Ungell
Rational approaches to drug design, 271-280
20 2001
ChemGPS: A chemical space navigation tool

TI Oprea, J Gottfries
Rational Approaches to Drug Design, 437-446
13 2001
Chemical information management in drug discovery: Optimizing the computational and combinatorial chemistry interfaces

TI Oprea, J Gottfries, V Sherbukhin, P Svensson, TC Kühler
Journal of Molecular Graphics and Modelling 18 (4), 512-524
46 2000
Correlation between experimental electron affinities for aromatic derivatives and the values calculated with semiempirical MO methods

M Mracec, TI Oprea, M Mracec
REVUE ROUMAINE DE CHIMIE 45 (10), 949-954
2000
Property distribution of drug-related chemical databases

TI Oprea
Journal of computer-aided molecular design 14 (3), 251-264
449 2000
Toward minimalistic modeling of oral drug absorption

TI Oprea, J Gottfries
Journal of Molecular Graphics and Modelling 17 (5), 261-274
107 1999
The design of leadlike combinatorial libraries

SJ Teague, AM Davis, PD Leeson, T Oprea
Angewandte Chemie International Edition 38 (24), 3743-3748
595 1999
Receptor-Based Prediction of Affinity

TI Oprea, GR Marshall
3D QSAR in Drug Design: Ligand-Protein Interactions and Molecular Similarity …
72* 1998
MTD-ADJ: A multiconformational minimal topologic difference for determining bioactive conformers using adjusted biological activities

T Sulea, L Kurunczi, TI Oprea, Z Simon
Journal of computer-aided molecular design 12 (2), 133-146
10 1998
Receptor-based prediction of binding affinities

TI Oprea, GR Marshall
Perspectives in Drug Discovery and Design 9, 35-61
68 1998
A different method for steric field evaluation in CoMFA improves model robustness

T Sulea, TI Oprea, S Muresan, SL Chan
Journal of chemical information and computer sciences 37 (6), 1162-1170
28 1997
Identification of a functional water channel in cytochrome P450 enzymes

TI Oprea, G Hummer, AE García
Proceedings of the National Academy of Sciences 94 (6), 2133-2138
113 1997
QSAR studies of disperse azo dyes. Towards the negation of the pharmacophore theory of dye-fiber interaction?

TI Oprea, L Kurunczi, S Timofei
Dyes and pigments 33 (1), 41-64
29 1997
Ligand-based identification of environmental estrogens

CL Waller, TI Oprea, K Chae, HK Park, KS Korach, SC Laws, TE Wiese, …
Chemical research in toxicology 9 (8), 1240-1248
205 1996
Three‐dimensional model of a selective theophylline‐binding RNA molecule

CS Tung, TI Oprea, G Hummer, AE Garcia
Journal of Molecular Recognition 9 (4), 275-286
5 1996
Three-dimensional quantitative structure-activity relationships of steroid aromatase inhibitors

TI Oprea, AE García
Journal of computer-aided molecular design 10 (3), 186-200
67 1996
VALIDATE: A new method for the receptor-based prediction of binding affinities of novel ligands

RD Head, ML Smythe, TI Oprea, CL Waller, SM Green, GR Marshall
Journal of the American Chemical Society 118 (16), 3959-3969
268 1996
The Analysis of Complexes from the Brookhaven Database for the Receptor-based Prediction of Binding Affinities of Novel Ligands

ML Smythe, MJ Dooley, Y Strandberg, ML West, TE Ramsdale, RD Head, …
Chemical Design Automation News 4 (11), 18-19
1996
PREDICTION OF AFFINITY-THE KEY TO DE-NOVO DRUG DESIGN

GR MARSHALL, RD HEAD, ML SMYTHE, SM GREEN, CMW HO, …
FASEB JOURNAL 9 (6), A1253-A1253
1995
Physical, Inorganic, and Analytical

TI Oprea, CMW Ho, GR Marshall
1995
3D QSAR and de novo design: choosing the appropriate tools

GR Marshall, CMW Ho, RD Head, ML Smythe, TI Oprea, CL Waller, …
QSAR and Molecular Modeling: Concepts, Computational Tools and Biological …
3 1995
The basis of cross-reactivity for a series of steroids binding to a monoclonal antibody against progesterone (DB3): A molecular modeling and QSAR study

TI Oprea, RD Head, GR Marshall
QSAR and molecular modelling: Concepts, computational tools and biological …
5 1995
De novo design: ligand construction and prediction of affinity

TI Oprea, CMW Ho, GR Marshall
ACS Symposium Series 589, 64-81
12 1995
3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.

TI Opera, CL Waller, GR Marshall
Drug design and discovery 12 (1), 29-51
50 1994
Three-dimensional quantitative structure-activity relationship of human immunodeficiency virus (I) protease inhibitors. 2. Predictive power using limited exploration of alternate binding modes

TI Oprea, CL Waller, GR Marshall
Journal of medicinal chemistry 37 (14), 2206-2215
110 1994
Conformational analysis and experimental dipole moments: a study of furan derivatives

L Kurunczi, TI Sulea, TI Oprea
Journal of Molecular Structure: THEOCHEM 306 (2-3), 93-100
2 1994
Three-dimensional quantitative structure-activity relationship of human immunodeficiency virus (I) protease inhibitors. 2. Predictive power using limited exploration of alternate binding modes

TI Oprea, CL Waller, GR Marshall
J. Med. Chem 37 (14), 2206-2215
117 1994
Viral proteases: Structure and function

TI Oprea, CL Waller, GR Marshall
Modern Cell Biology 15, 183-183
2 1994
Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentally-determined alignment rules

CL Waller, TI Oprea, A Giolitti, GR Marshall
Journal of medicinal chemistry 36 (26), 4152-4160
181 1993
MOLECULAR RECOGNITION DURING LIGAND-RECEPTOR INTERACTIONS. APPLICATIONS IN RECEPTOR MAPPING

TI Oprea, L Kurunczi
Specific Interaction and Biological Recognition Processes, 295
1993
Multiconformational Minimal Steric Difference. Structure‐Acetylcholinesterase Hydrolysis Rates Relations for Acetic Acid Esters

D Ciubotariu, E Deretey, TI Oprea, T Sulea, Z Simon, L Kurunczi, …
Quantitative Structure‐Activity Relationships 12 (4), 367-372
34 1993
Comparison of the minimal steric difference (MTD) and comparative molecular field analysis (CoMFA) methods for analysis of binding of steroids to carrier proteins

TI Oprea, D Ciubotariu, TI Sulea, Z Simon
Quantitative Structure‐Activity Relationships 12 (1), 21-26
38 1993
Cheminformatics-Advanced: Data Analysis, Classification Methods, Quantitative Structure-Activity Relationships (QSAR)

DC Fara, TI Oprea
Computational Chemogenomics

H Koeppen, M Bieler, JL Reymond, L Ruddigkeit, M Awale, P Mukherjee, …
3.14-Bioactivity Databases

M Olah, TI Oprea
Elsevier Ltd
Supplementary information: ChemProt-3.0: A global chemical-biology diseases mapping

J Kringelum, SK Kjærulff, TI Oprea, S Brunak, OL Olivier
Computational Medicinal Chemistry for Drug Discovery

I Pettersson, T Liljefors, K Gundertofte, PO Norrby, T Bredow, J Poul, …
A Disease Chemical Biology Database

O Taboureau, TI Oprea
UNMCMD Probe Report Title: Three small molecule pan activator families of Ras-related GTPases

Z Surviladze, O Ursu, F Miscioscia, R Curpan, L Halip, C Bologa, T Oprea, …
Substance 501, 57578335